Dextromethorphan Versus Placebo for Neuropathic Pain
Launched by NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH (NIDCR) · Dec 9, 2002
Current as of December 03, 2023
In our current clinical trial, we are comparing the effects of two NMDA receptor antagonists to placebo in patients with painful distal symmetrical diabetic neuropathy or post-herpetic neuralgia. The treatments in this three-period crossover study are dextromethorphan, up to 920 mg/day (about 8 times the antitussive dose), memantine, 30-50 mg/day, and placebo. Memantine is an NMDA antagonist used in Europe to treat Parkinson's disease and Alzheimer's disease. The underlying hypothesis, based on studies of painful neuropathies in animal models, is that neuropathic pain is caused largely by s...
- Patients must be over 18 years of age.
- Patients must have a definite diagnosis of diabetic neuropathy or post herpetic neuralgia or a diagnosis of neuropathic pain of various etiologies other than diabetic neuropathy or post herpetic neuralgia.
- Duration of symptoms must be at least 3 months.
- Severity of pain must be at least mild, if constant; or at least moderate, if intermittent and at least 2 hours duration a day.
- Patients using tricyclics, narcotics, or antiseizure medications, must keep the drug dosages constant throughout the study.
- No patients with unstable disease process; i.e., angina pectoris, accelerated hypertension, recent stroke or transient cerebral ischemia, uncontrolled seizures.
- No pregnant or lactating women. Women of child bearing potential must use birth control pills, intrauterine device, or barrier contraceptive devices.
- No history of significant drug abuse or PCP use. No history of IV drug abuse, prescription drug abuse, or alcoholism.
- No significant liver or kidney disease.
- No MAO inhibitors.
- No cognitive impairment or language difficulty as judged by difficulty completing pain diary, medical history, or telephone conversation.
- Patients must not have any other chronic pain condition that gives them pain greater than the neuropathy pain.
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
All reviews come from applied patients